How to switch from other heart failure medications to Entresto?

This comprehensive guide will walk you through the process of transitioning from various heart failure medications to Entresto, a medication that has shown to improve outcomes in patients with heart failure with reduced ejection fraction. We will cover the reasons for switching, how to manage the transition safely, potential side effects, and monitoring during the process.

Understanding Heart Failure and Current Medications

Heart failure is a chronic condition where the heart is unable to pump adequately to meet the body's needs. It can lead to a variety of symptoms and impact the quality of life. Current medications for heart failure include ACE inhibitors, ARBs, beta-blockers, diuretics, and others that aim to manage symptoms and prevent hospitalizations. Entresto is a combination of sacubitril and valsartan. It has been shown to reduce the risk of cardiovascular death and hospitalization in heart failure patients compared to traditional therapies.

Reasons to Switch to Entresto

One primary reason to switch to Entresto is the growing evidence that it improves outcomes more effectively compared to traditional medications. Patients who remain symptomatic or have frequent hospitalizations may benefit significantly by switching to Entresto. Moreover, when patients experience side effects from ACE inhibitors or ARBs, Entresto may be a suitable alternative.

Pre-Switch Assessment

Before switching medications, conduct a thorough assessment of the patient's current health status, including blood pressure, renal function, and electrolyte levels. Review all current medications to assess potential drug interactions, especially with other medications the patient may be taking. Discuss with the patient the benefits and possible side effects of Entresto to ensure they are informed and consent to the switch.

Step-by-Step Guide to Switching to Entresto

Step 1: Gradual Reduction - Taper off the current heart failure medications. This process may vary depending on the medications being used. Step 2: Washout Period - If transitioning from an ACE inhibitor, a 36-hour washout period should be observed before starting Entresto to reduce the risk of angioedema. Step 3: Initiating Entresto - Start patients on Entresto at the recommended initiating dose based on their prior medication and renal function. Step 4: Patient Education - Educate the patient on how to take Entresto properly, such as the importance of adhering to prescribed dosing and recognizing possible side effects.

Monitoring After Transition

Regularly monitor the patient's blood pressure, renal function, and electrolytes after switching to Entresto. This should occur within the first few weeks of starting therapy. Evaluate the patient's response to the medication, noting any symptomatic improvements or adverse reactions. Schedule follow-up appointments to adjust dosages if needed, based on how well the patient is tolerating Entresto.

Potential Side Effects and Management

Common side effects of Entresto include hypotension, hyperkalemia, and renal impairment. It is crucial to be aware of these and manage them appropriately. Educate patients on the signs of hypotension, such as dizziness or fainting, and advise them to seek help if they experience these symptoms. For patients experiencing hyperkalemia, consider dietary sodium and potassium restrictions and adjust dosage accordingly.

Long-Term Considerations

Long-term management of heart failure with Entresto includes periodic reassessment of heart function, overall health, and lifestyle modifications. Encourage adherence to recommended lifestyle changes, including dietary adjustments, exercise, and regular medical appointments. Consider cardiac rehabilitation referral for additional support in managing heart failure.